PolyPid (PYPD) raises ordinary share Sales Agreement capacity

Rhea-AI Filing Summary

PolyPid Ltd. (PYPD) reports that on November 26, 2025 it increased the maximum aggregate offering price of its ordinary shares issuable under its Sales Agreement with Oppenheimer & Co. Inc. from $8,250,000 to $15,000,000. This Sales Agreement, dated November 8, 2024, allows PolyPid to issue and sell ordinary shares from time to time, typically in an at-the-market structure.

The company also filed a legal opinion from Sullivan & Worcester Tel-Aviv (Har-Even & Co.) as Exhibit 5.1, addressing the legality of issuing and selling these ordinary shares under the Sales Agreement. This report is incorporated by reference into multiple existing PolyPid shelf registration statements on Form F-3 and equity compensation registration statements on Form S-8, so that future share sales under the Sales Agreement can rely on this updated disclosure.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: November 2025 (Report No. 2)

Commission File Number: 001-38428

PolyPid Ltd.

(Translation of registrant’s name into English)

18 Hasivim Street

Petach Tikva 495376, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

CONTENTS

On November 26, 2025, PolyPid Ltd. (the “Registrant”) increased the maximum aggregate offering price of its ordinary shares, no par value per share, (the “Ordinary Shares”) issuable under its Sales Agreement (the “Sales Agreement”) with Oppenheimer & Co. Inc., dated November 8, 2024, from $8,250,000 to $15,000,000. A copy of the opinion of Sullivan & Worcester Tel-Aviv (Har-Even & Co.) relating to the legality of the issuance and sale of the Ordinary Shares that may be sold pursuant to the Sales Agreement is attached as Exhibit 5.1 hereto.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658, File No. 333-281863, File No. 333-284376 and File No. 333-289034)  and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703, File No. 333-280662 and File No. 333-289570) filed  with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

EXHIBIT INDEX

Exhibit No.
5.1		Opinion of Sullivan & Worcester Tel-Aviv (Har-Even & Co.)
23.1		Consent of Sullivan & Worcester Tel-Aviv (Har-Even & Co.)(contained in Exhibit 5.1)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	POLYPID LTD.
Date: November 26, 2025	By:	/s/ Dikla Czaczkes Akselbrad
		Name	: Dikla Czaczkes Akselbrad
		Title:	Chief Executive Officer

3

FAQ

What did PolyPid Ltd. (PYPD) change in its November 2025 Form 6-K?

PolyPid Ltd. increased the maximum aggregate offering price of its ordinary shares under its Sales Agreement with Oppenheimer & Co. Inc. from $8,250,000 to $15,000,000.

Which agreement is affected by PolyPids new $15,000,000 capacity?

The change applies to PolyPids Sales Agreement with Oppenheimer & Co. Inc., dated November 8, 2024, covering issuances and sales of its ordinary shares.

Did PolyPid file a legal opinion with this 6-K filing?

Yes. PolyPid filed an opinion of Sullivan & Worcester Tel-Aviv (Har-Even & Co.) as Exhibit 5.1, addressing the legality of issuing and selling ordinary shares under the Sales Agreement.

How does this Form 6-K relate to PolyPids existing F-3 shelf registrations?

The report is incorporated by reference into PolyPids registration statements on Form F-3 (File Nos. 333-276826, 333-280658, 333-281863, 333-284376 and 333-289034), making this disclosure part of those shelves.

Are PolyPids employee benefit plans affected by this 6-K?

The report is also incorporated by reference into PolyPids Form S-8 registration statements (File Nos. 333-239517, 333-271060, 333-277703, 333-280662 and 333-289570), aligning this disclosure with its equity compensation plans.

Who signed PolyPid Ltd.s November 2025 Form 6-K?

The Form 6-K was signed on behalf of PolyPid Ltd. by Dikla Czaczkes Akselbrad, its Chief Executive Officer.